Press

Sierra Sage Herbs Acquired By Creso Pharma

Feb 7 • 5 min read

Sierra Sage Herbs, maker of the best-selling Green Goo, Southern Butter and Good Goo natural products brands, announced today its acquisition by Australia’s Creso Pharma Limited (ASX: CPH, OTC: COPHF, FRA: 1X8). The deal extends Creso’s global footprint to the US market while adding an additional range of natural health products to its existing lines of cannabis and hemp-based pharmaceuticals. Sierra Sage, which counts 90,000…

Tryp Therapeutics Announces $2,000,000 Financing and Changes in Management, Board of Directors

Feb 4 • 4 min read

Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, is pleased to announce a non-brokered private placement to its co-Founder and Executive Director, William J. Garner, M.D. The Placement consists of 11,111,111 million units at a price of $0.18 per Unit, to raise gross proceeds of approximately $2.0 million. Each Unit…

Entheon Biomedical Announces the Approval of DMT Clinical Trial

Feb 3 • 3 min read

Entheon Biomedical Corp. (CSE: ENBI), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announced today the approval by the local Dutch ethics committee of EBRX-101, a comprehensive phase I clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of N,N-dimethyltryptamine (DMT)….

Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001

Feb 2 • 4 min read

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced in preparation for its FDA pre-Investigational New Drug (IND) meeting on February 28th, the company has submitted a pre-IND briefing package to the U.S. Food and Drug Administration (FDA)…

PharmaDrug Announces Filing of US Provisional Patent for Cepharanthine to Treat Prostate Cancer

Feb 1 • 6 min read

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has filed a US provisional patent application which details the novel synergistic combination of cepharanthine (PD-001) and cabazitaxel…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441